News and Press Releases

Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year

Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at phase 2 remain high 16 January 2024 --...

Category: Clinical Trials
Posted: January 16, 2024

East Lyme, Connecticut, US

Headlands Research Announces Partnership with Sahara Behavioral Health

The collaboration improves access to clinical research and investigational treatments while supporting participant recruitment efforts in Arizona 4 January 2024 -- California, US -- Headlands Research, a leading multinational network...

Category: Clinical Trials
Posted: January 5, 2024

130 John F Kennedy Dr STE 203 Lake Worth, FL 33462

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

5 January 2024 -- Helsinki, Finland -- Nanoform Finland, the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate...

Category: Clinical Trials
Posted: January 5, 2024

Cultivator II, Viikinkaari 4 FI-00790 Helsinki, Finland

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer

The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO CongressLazertinib is a highly selective, central...

Category: Clinical Trials
Posted: December 21, 2023

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study

14 December 2023 -- London, UK -- Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialised healthcare brands, have today announced the completion of enrolment of...

Category: Clinical Trials
Posted: December 14, 2023

unit 1, 120 Weston St, London SE1 4XE

PlaqueTec recruits first ten patients in BIOPATTERN trial

Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...

Category: Clinical Trials
Posted: November 29, 2023

Maia Building (B270) Babraham Research Campus Cambridge CB22 3AT

Exonate announces successful completion of phase 1b/2a trial in diabetic macular oedema

Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema EXN407 met all endpoints and displayed encouraging biological activity in diabetic patients with...

Category: Clinical Trials
Posted: November 28, 2023

WTL Moorfield Rd Duxford Cambridgeshire CB22 4PS United Kingdom

Janssen Submits Application to the European Medicines Agency forRYBREVANT▼ (amivantamab) in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy

The submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of...

Category: Clinical Trials
Posted: November 23, 2023

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

CluePoints wins SCRIP Awards for Best Contract Research Organisation (CRO): Specialist Providers

Company wins prestigious accolade for commitment to innovation and education 17 November 2023 -- Pennsylvania, US -- CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management (RBQM) software for...

Category: Clinical Trials
Posted: November 22, 2023

1000 Continental Drive, Suite 240, King of Prussia, PA 19406

Commercial study set up times reduced by a third, according to new data 

26 October 2023 -- London, England -- New data from the National Institute for Health and Care Research (NIHR) shows that the National Contract Value Review has significantly reduced the...

Category: Clinical Trials
Posted: October 26, 2023

Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy

Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...

Category: Clinical Trials
Posted: October 23, 2023

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

PharmaKure announces study success for novel blood test to identify biomarkers in patients with Alzheimer’s Disease

Study confirms ALZmetrix whole blood test can detect people at high risk of developing full Alzheimer’s Disease 17 October 2023 -- Manchester, UK -- PharmaKure, a pharmaceutical company spun out...

Category: Clinical Trials, Drug Discovery
Posted: October 17, 2023

Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG

AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023

Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...

Category: Clinical Trials
Posted: October 12, 2023

PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

Phastar Net-Zero Target Approved by the Science Based Targets Initiative

Phastar commits to achieving Net-Zero Standard by 2035 4 October 2023 -- London, UK, and North Carolina, US -- Phastar, a global specialist biometrics contract research organisation (CRO), has had...

Category: Drug Discovery
Posted: October 6, 2023

Unit 2, 2A Bollo Ln, Chiswick, London W4 5LE

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...

Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023

Global Headquarters 200 Technology Square Cambridge, MA 02139